Alejandro Martín García-Sancho-rekin lankidetzan egindako argitalpenak (6)

2024

  1. Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 17, pp. 3704-3714

2019

  1. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group

    British Journal of Haematology, Vol. 184, Núm. 5, pp. 797-807

  2. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

    Cancer Medicine, Vol. 8, Núm. 16, pp. 6955-6966

2006

  1. Treatment options in relapsed or refractory Hodgkin disease patients: The mini-BEAM regimen does exist too [1]

    British Journal of Haematology

2001

  1. Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease

    Haematologica, Vol. 86, Núm. 5, pp. 494-498

  2. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease

    British Journal of Haematology, Vol. 113, Núm. 1, pp. 161-171